Sohini Das &Amp; Samreen Ahmad

Stories by Sohini Das &Amp; Samreen Ahmad

Post sale of Future group, Biyani will keep home retailing biz going

Post sale of Future group, Biyani will keep home retailing biz going

Rediff.com   11 Sep 2020

Future's home retailing interests, including furniture and furnishings, are housed under Praxis Home Retail, which was created in FY18 when the group demerged the business from Future Retail.

India will wait for DCGI nod to restart Oxford vaccine trial

India will wait for DCGI nod to restart Oxford vaccine trial

Rediff.com   11 Sep 2020

The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.

PUBG Mobile sheds China link to woo Indian gamers

PUBG Mobile sheds China link to woo Indian gamers

Rediff.com   9 Sep 2020

Even though PUBG Corporation is a South Korean company with its headquarters in Seoul, Tencent Gaming, a subsidiary of Chinese investment and technology giant Tencent, holds the global franchise for the mobile version of the game.

Edtech start-up Eruditus gets funding from Zuckerberg duo

Edtech start-up Eruditus gets funding from Zuckerberg duo

Rediff.com   7 Sep 2020

Eruditus runs on a partnership model with top global universities such as MIT, Columbia, Harvard, Cambridge, INSEAD, Wharton, and UC Berkeley, offering courses in coding, data science, fintech, block chain, and entrepreneurship.

With coronavirus still around, 'virus killers' hit the market

With coronavirus still around, 'virus killers' hit the market

Rediff.com   7 Sep 2020

A gamechanger for offices and factories, Shycocan, claims to be able to clear an area of 1000 square feet from coronavirus.

Can Gondal's FAU-G tackle PUBG's withdrawal pangs?

Can Gondal's FAU-G tackle PUBG's withdrawal pangs?

Rediff.com   5 Sep 2020

According to nCore Games, FAU-G will be based on real scenarios encountered by the Indian security forces to deal with both domestic and foreign threats, with its first level set against the Galwan Valley backdrop. The start-up is planning to monetise the venture through in-game purchase where people will be able to buy better items in the game like better armour for an enhanced gaming experience.

In the works: Priority list of who will get Covid vaccine first

In the works: Priority list of who will get Covid vaccine first

Rediff.com   4 Sep 2020

The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.

Indian pharma firms working on new repurposed drug for Covid-19

Indian pharma firms working on new repurposed drug for Covid-19

Rediff.com   2 Sep 2020

Many companies globally are working on plasma research to develop and manufacture hyperimmune globulin therapies from plasma donations.

Pandemic brings windfall for e-pharma companies

Pandemic brings windfall for e-pharma companies

Rediff.com   27 Aug 2020

The online pharmacy market, which was worth about $512 million in 2018, is growing at a CAGR of 63 per cent and is expected to hit overall revenues of over $3.6 billion by 2022.

How India's healthcare system will change forever

How India's healthcare system will change forever

Rediff.com   27 Aug 2020

The National Digital Health Mission seeks to provide a unique health ID to each citizen who wishes to have one and also on-board the healthcare service provides - hospitals, pharmacies and diagnostic labs, among others. It will have an online database of doctors and personal health records.

'Cipla has emerged as a great catchment area for talent'

'Cipla has emerged as a great "catchment area" for talent'

Rediff.com   20 Aug 2020

An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Rediff.com   19 Aug 2020

The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.

Despite Covid woes, residential launches back on track

Despite Covid woes, residential launches back on track

Rediff.com   18 Aug 2020

Despite a 56 per cent fall in residential launches in the first half of the year compared to the second half of 2019, Anarock Property Consultants believes that consolidation in residential real estate is expected to gain ground, and that branded players may garner a market share of 75-80 per cent.

Covid drug sales shine even as market slows

Covid drug sales shine even as market slows

Rediff.com   18 Aug 2020

Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.

Fortis to re-brand itself as Parkway

Fortis to re-brand itself as Parkway

Rediff.com   15 Aug 2020

The company said this was 'important' to reinforce the 'complete disassociation' from its erstwhile promoters -- Malvinder and Shivinder Singh.

How govt plans to distribute Covid-19 vaccine

How govt plans to distribute Covid-19 vaccine

Rediff.com   13 Aug 2020

The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured.

After showing signs of recovery, pharma sales dip in July

After showing signs of recovery, pharma sales dip in July

Rediff.com   11 Aug 2020

Growth has been under pressure since the lockdowns related to Covid-19 started and fresh prescription generations slowed.

E-com giants may see 25% jump in sales

E-com giants may see 25% jump in sales

Rediff.com   10 Aug 2020

Instead of making the sellers bleed, experts say, e-commerce giants Amazon and Flipkart have roped in banks to offer discounts to buyers.

Serum Institute to provide Covid vaccine at Rs 250 a dose

Serum Institute to provide Covid vaccine at Rs 250 a dose

Rediff.com   8 Aug 2020

Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.

Meet Adar Poonawala, India's COVID-19 vaccine man

Meet Adar Poonawala, India's COVID-19 vaccine man

Rediff.com   6 Aug 2020

Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.